Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538743 · ClinicalTrials.gov registry record · Phase 1
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
A Phase 1 study of Type 2 Diabetes Mellitus, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 4
- Study locations
NCT03538743 is a Phase 1 study of Type 2 Diabetes Mellitus that has completed, run by Pfizer. The registered enrollment target is 98 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT03538743, a Phase 1 study of Type 2 Diabetes Mellitus, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-06882961
Study Locations (4)
Florida
- Qps-Mra, Llc - South Miami
- Qps-Mra,Llc - South Miami
California
- Anaheim Clinical Trials, LLC - Anaheim
Kansas
- Altasciences Clinical Kansas, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2018-06-25 |
| Est. Completion | 2019-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03538743
The ClinicalTrials.gov registry entry for NCT03538743 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (96% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03538743 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Kansas.
Frequently Asked Questions
What is clinical trial NCT03538743 about?
NCT03538743 is a clinical study titled "4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes". This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.
What is the current status of trial NCT03538743?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2018-06-25. Estimated completion is 2019-06-10.
What conditions does trial NCT03538743 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT03538743?
The interventions under investigation include: Placebo (DRUG), PF-06882961 (DRUG).
Who is sponsoring clinical trial NCT03538743?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03538743 being conducted?
This trial has 4 study locations across California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
COMPLETED · Phase 1
-
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
COMPLETED · Phase 1
-
A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol
COMPLETED · Phase 1
-
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.